Prognostic Risk Stratification of Acute Coronary Syndrome Role of Highly Sensitive C-Reactive Protein by Dhanasekar, M
 P a g e  | 1 
 
Prognostic Risk Stratification of Acute 
Coronary Syndrome Role of Highly Sensitive          
C - reactive protein  
 
 
A Dissertation Submitted to 
THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY 
CHENNAI 
 
 
In Partial Fulfillment of the Regulations 
for the Award of the Degree of 
M.D. (GENERAL MEDICINE) - BRANCH – I 
 
 
 
 
 
 
 
 
 
 
 
 
GOVERNMENT KILPAUK MEDICAL COLLEGE 
CHENNAI 
April - 2013 
 
 P a g e  | 2 
 
Bonafide Certificate 
 
 
This is to certify that PROGNOSTIC RISK STRATIFICATION 
OF ACUTE CORONARY SYNDROME ROLE OF HIGHLY 
SENSITIVE C-REACTIVE PROTEIN is a Bonafide work done by              
Dr. M. DHANASEKAR., Post Graduate Student, Department of Internal 
Medicine, Government Kilpauk Medical College, Chennai-10, under my 
guidance and supervision in partial fulfillment of regulations of                       
The Tamil Nadu  Dr. M.G.R. Medical University for the award of M.D. 
Degree Branch I (General Medicine) during the academic period from 
September 2011 and August 2012. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prof. Dr. N.GUNASEKARAN, M.D., DTCD, 
Director & Medical Superintendent,  
GRH & INCD, Professor and Head of the 
Department of Medicine,  
Govt. Kilpauk Medical College Hospital,   
Chennai-10 
Dr. D. Surendran, M.D., 
Professor of Medicine, 
Unit Chief, Govt. Kilpauk Medical College 
Hospital, Chennai – 10.   
 
Prof. P. Ramakrishnan, M.D., D.L.O., 
The Dean, 
Govt. Kilpauk Medical College, 
Chennai – 600 010 
 
 P a g e  | 3 
 
Declaration 
  
I DR. M. DHANASEKAR solemnly declare that this dissertation 
“
PROGNOSTIC RISK STRATIFICATION OF ACUTE CORONARY 
SYNDROME ROLE OF HIGHLY SENSITIVE C-REACTIVE 
PROTEIN” was prepared by me at Government Kilpauk Medical College 
and Hospital, Chennai, under the guidance and supervision of                            
Prof. Dr. D. SURENDRAN, M.D. Professor of Internal Medicine, Govt. 
Kilpauk Medical College and Hospital, Chennai. 
 
This dissertation is submitted to The Tamil Nadu Dr. M.G.R. 
Medical University, Chennai in partial fulfillment of the University 
regulations for the award of the degree of M.D. Branch I (General 
Medicine). 
 
 
Place : Chennai 
Date :                                                                     (Dr. M. DHANASEKAR) 
        
 
 
 
 
 
 
 
 P a g e  | 4 
 
Acknowledgement 
 
   
At the outset, I would like to thank my beloved Dean, Kilpauk 
Medical College, Prof. Dr. P.RAMAKRISHNAN, M.D., D.L.O., for his 
kind permission to conduct the study at Kilpauk Medical College.  
 
I would like to express my special thanks to the medical 
superintendent Prof.Dr.V.JAYARAMAN, M.S.M.Ch, Plastic Surgery for 
Permitting me to conduct this study at Kilpauk Medical College Hospital. 
 
It gives me immense pleasure to express my deep gratitude to                
Prof. Dr. N.GUNASEKARAN, M.D., DTCD, Director & Medical 
Superintendent, GRH & INCD, Professor and Head of the Department of 
Medicine, Govt. Kilpauk Medical College Hospital for rendering permission to do 
this dissertation. I would also thanking whole heartedly for his encouragement and 
guidance during the study.  
 
I would like to thank wholeheartedly Prof. Dr. G.BALAN M.D., 
Professor of Internal Medicine, Government Kilpauk Medical College and 
Hospital for his continuous encouragement, guidance and constant 
supervision during the study.  
 
It gives me immense pleasure to express my deep gratitude to 
Dr.D.SURENDRAN, M.D. Professor of Medicine and Unit chief for his 
support and positive criticism to keep me on track.  
 
There are no words to express my indebtedness to 
Dr.G.GNANAVEL, M.D., D.M., Professor and Head of Department of 
cardiology, Kilpauk Medical College Hospital for his continuous support 
both academically and morally; for providing me with clinical materials; 
reviewing periodically for progress and permitting me to conduct my study 
at the department of Cardiolgy. 
 P a g e  | 5 
 
I would like to express my thanks to Prof. 
Dr.THYAGARAJANRAVINDER, M.D., Professor and Head of the 
Department of Microbiology, Kilpauk medical college for all the help 
rendered in doing the hs-CRP assay.   
 
I would like to immensely thank Prof. Dr. S. NAGENDRAN, M.D., 
Head of Department of Biochemistry for all the help rendered to me in doing 
cTnT in Biochemistry department, Kilpauk medical college. 
 
I am extremely thankful to Prof. Dr. P. S. MOHANA MURUGAN, 
M.D., D.M., formerly Professor & Head, Department of Cardiology, 
Kilpauk Medical College Hospital, Chennai, for permitting me to utilise the 
facilities in the department and for his valuable academic advice. 
 
I am deeply indebted to Prof. Dr. K. V. S. LATHA, M.D., formerly 
Professor of Medicine, Kilpauk Medical College, for her moral support and 
academic guidance.  
 
I also thank Prof. Dr.T.RAVINDRAN, M.D., and Prof.                          
Dr. S. USHA LAKSHMI, M.D. for their guidance. 
 
I am extremely thankful to Assistant Professor of Medicine, Kilpauk 
Medical College, Dr. D. VENKATESHWARLU, M.D., for his valuable 
suggestions and guidance throughout the work. 
 
I would always remember with extreme sense of thankfulness for the 
co-operation and criticism shown by my postgraduate colleagues and my 
family. 
Finally, I wholeheartedly thank all my patients for their active co-
operation in this study, without which this would not have become a reality.
 P a g e  | 6 
 
 
 P a g e  | 7 
 
Table of Contents 
1. INTRODUCTION ........................................................................ 01 
2. AIM .............................................................................................. 04 
3. LITERATURE REVIEW .............................................................. 05 
4. MATERIALS AND METHODS ................................................... 47 
5. RESULTS .................................................................................... 52 
6. DISCUSSION .............................................................................. 72 
7. CONCLUSION ............................................................................ 78 
BIBLIOGRAPHY ............................................................................. 79 
ANNEXURE : A  PROFORMA .............................................. 91 
ANNEXURE : B  MASTER  CHARTS   .................................. 94 
ANNEXURE : C  ABBREVIATION ............................. .........102 
ANNEXURE : D  ethical committee certificate .. ........ 104 
 
 P a g e  | 8 
 
INTRODUCTION 
 Acute coronary syndrome is an umbrella term which involves a varied 
spectrum of clinical manifestations suggesting myocardial ischemia. It varies from 
benign to potentially fatal illness.
1
 Acute chest pain is one of the most common 
reasons for presentation to the emergency department. This presentation suggests 
acute coronary syndrome (ACS), but after diagnostic evaluation, only 15% to 25% 
of patients with such symptom actually have ACS.
2,3 
 
The usual clinical tools for risk stratification such as History, Physical 
Examination, ECG, Lipid Profile may be inadequate in diagnosis of MI in 
approximately 2% of patients, leading to short term mortality for patients with 
Acute MI, who are mistakenly discharged from Emergency department.  These 
missed cases are about more than two-fold over the expected for patients who are 
admitted to the hospital.
3
 This has led to the search for circulating markers that 
establish the diagnosis better. 
   
Atherosclerosis, is a process which starts in the early childhood and 
progresses slowly with out manifesting any symptoms for decades. 
Atherosclerosis is not simply a disease of lipid deposition but it also 
inflammation.
4 
 
Histological picture from an atheromatous plaque showed the presence of 
inflammatory cells like macrophages, T- Lymphocytes and Monocytes. These 
inflammatory cells are most abundant in the shoulder region of the plaque. This 
region is the most common site of plaque rupture in ACS. 
5-8 
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As inflammation has a key role in the pathogenesis of coronary artery 
disease, CRP, a marker for inflammation, is a prognostic marker for stable angina 
pectoris, unstable angina and non-Q wave MI.
9,10
 In addition to CRP, cardiac 
specific Troponin “T” (cTnT) a very sensitive and specific marker of myocardial 
necrosis has also been associated with better identification of patients having  
increased risk from cardiac events resulting in death and subsequent non fatal 
MI.
11
   
 
cTnT has only one assay for its measurement and thus it demonstrates high 
degree of precision at the low end of measurement range and a relatively uniform 
cut off concentration.
 
These biomarkers may be mutually complementary to each 
other and so multi marker testing would be  helpful in better characterizing each 
case of ACS. (Fig 1) 
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Figure 1. Biomarkers in acute coronary syndrome 
 
In our prospective study, we decided to investigate the association of hs-
CRP and cTnT obtained in patients with ACS and development of nonfatal MI 
and all cause mortality with in 14 days. Previous studies have little information 
regarding the association between highly sensitive CRP and cTnT in the adverse 
events of patient with ACS. 
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AIM AND OBJECTIVES 
 
Aim 
To access the association of  hs- CRP  and  cTnT  after 6 hours of 
admission in patients  having ACS with nonfatal MI and  Mortality with in 14 
days.  
 
 
Objectives 
To evaluate highly sensitive CRP alone and in conjunction with cTnT as 
predictor of  risk of individual end points of All cause Mortality and MI with in 14 
days  in patients  admitted  in the  Emergency dept and ICCU  of Cardiology Dept 
in Kilpauk Medical College Hospital. 
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REVIEW OF LITERATURE 
 
UA/NSTEMI is commonly due to severe obstruction, but not total 
occlusion, of the culprit coronary artery. The incidence of NSTE-ACS, is 
increasing, probably due to demographic changes in the population, including 
progressively increasing numbers of older persons and higher rates of diabetes and 
hypertension.
12
 According to OASIS registry, Indian patients are 7 to 8 years 
younger than western patients with mean age of 57 years
   
as against 65 years in 
western population. According to CREATE registry in the year 2008,  20,000 
patients admitted in multiple centres in india, 33 percent of this patients were less 
than 50 years of age. Smoking was the risk factor in 50% patients. The mortality 
rate of NSTEMI was 4% which is 1% more than in western population.
13 
 
Definition
 
Stable angina pectoris typically manifests as a deep, poorly localized chest 
or arm discomfort or pain, reproducibly precipitated by physical exertion or 
emotional stress, and relieved within 5 to 10 minutes by rest or sublingual 
nitroglycerin.  In contrast, unstable angina is defined as “angina pectoris (or 
equivalent type of ischemic discomfort) with at least one of the three features: (1) 
occurring at rest (or minimal exertion) and usually lasting >20 minutes, (2) being 
severe and usually described as frank pain; or (3) occurring with a crescendo 
pattern (i.e., pain that awakens the patient from sleep or that is more severe, 
prolonged, or frequent than previously)”.  
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Pathophysiology 
Five patho physiologic processes contribute to the development of 
UA/NSTEMI,
14  
shown in Fig 2. 
 
1. Plaque rupture or erosion with superimposed  non occlusive thrombus, 
2. Dynamic obstruction due to 
a. Spasm of an epicardial coronary artery,  
b. Local vasoconstrictors, such as thromboxane A2, released from 
platelets;   
c. constriction of the small, intramural muscular coronary arteries, that is, 
the coronary resistance vessels, 
d. adrenergic stimuli including cocaine and cold and 
e. dysfunction of the coronary endothelium;  
 
3. Inflammation and  
4. Severe coronary luminal narrowing caused by progressive coronary 
atherosclerosis or post–percutaneous coronary intervention restenosis; 
5. Secondary unstable angina, that is, severe myocardial ischemia due to 
increased myocardial oxygen demand or decreased oxygen supply (e.g., 
tachycardia, fever, hypotension, or anemia). 
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Individual patients may have several of these processes coexisting as the cause of 
UA/NSTEMI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Causes of unstable angina (UA) 
MVO2 = myocardial O2 consumption. 
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ACS is the manifestation of sudden plaque rupture with subsequent 
occlusive or subocclusive thrombus formation, leading to distal myocardial 
ischemia or myonecrosis (Fig 3).
15
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure - 3. Various presentations of ACS 
 
Cardiac muscle Necrosis disrupts the structure of sarcolemmal membrane. 
Following the disruption intracellular macromolecules (cardiac enzymes) begins 
to diffuse in to the cardiac interstitium,vasculature and lymphatics surrounding the 
infarct. 
16,17
  The rate of appearance of these macromolecules in the peripheral 
circulation depends on several factors, including intracellular location, molecular 
weight, local blood and lymphatic flow, and rate of elimination from the 
blood.
18
(Fig 4)
 
. 
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Figure 4 
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Cardiac Bio Markers Predicting Unstable Angina and NSTEMI are, 
 Increased troponin T or I or creatine kinase–MB  
 Increased C-reactive protein or white blood cell count  
 Increased B-type natriuretic peptide  
 Elevated creatinine  
 Elevated glucose or hemoglobin A1c  
Cardiac bio markers predicting
 
STEMI are shown in (Table 1),  
 
 
Table 1 Biomarkers for Evaluation of Patients with STEMI 
 
Biomarker 
 
Molecular 
Weight (Da) 
Time Of  
Elevation 
(Hr) 
Time of Peak 
Elevations 
(Nonreper 
fused) 
Time To 
Return To 
Normal 
 
CK-MB 
 
86,000 
 
3-12 
 
24 hr 
 
48-72 hr 
 
C TnI 
 
23,500 
 
3-12 
 
24 hr 
 
5-10 days 
CtnT 33,000 3-12 12 hr-2 days 5-14 days 
Myoglobin 17,800 1-4 6-7 hr 24 hr 
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These serum markers form the foundation of a “multimarker strategy” for 
evaluation and risk stratification of UA/NSTEMI patients. (Fig. 5) 
 
 
 
 
 
 
 
 
 
 
 
Fig 5. A multimarker strategy for evaluation of the etiology and prognosis 
of UA/NSTEMI. In addition, these now have been seen to be independent markers 
of an adverse prognosis. BNP = B-type natriuretic peptide; CrCl = creatinine 
clearance; Hb A1c = hemoglobin A1c; hs-CRP = high-sensitivity C-reactive 
protein; NT-proBNP = N-terminal pro-BNP; UA/NSTEMI = unstable angina or 
non–ST elevation myocardial infarction.
 
 
Clinical Classification  
A clinical classification of  UA/NSTEMI 
19
 (Table 2)  provides a useful 
means to stratify risk. Patients fall into three groups according to the clinical 
circumstances of the acute ischemic episode: (1) primary unstable angina caused 
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by reductions of myocardial perfusion (2) secondary unstable angina (e.g., with 
ischemia related to precipitating factors such as anemia or an acute MI), and (3) 
post-MI unstable angina. Patients are classified simultaneously according to the 
severity of the ischemia. This classification provides valuable prognostic 
information (with postinfarction angina at rest having the worst prognosis). 
 
Table 2 Braunwald Classification of Unstable Angina (UA) 
Severity 
Clinical Circumstances 
A B C 
Develops in 
presence of extra 
cardiac condition 
that intensifies 
myocardial 
ischemia 
(secondary UA) 
Develops in 
the absence of 
extra cardiac 
condition 
(primary UA) 
Develops 
within 2 weeks 
after acute 
myocardial 
infarction (post 
infarction UA) 
I 
New onset of 
severe angina or 
accelerated 
angina; no rest 
pain 
IA IB IC 
II 
Angina at rest 
within past month 
but not within 
preceding 48 hr 
(angina at rest, 
sub acute) 
IIA IIB IIC 
III 
Angina at rest 
within 48 hr 
(angina at rest, 
acute) 
IIIA 
IIIB Troponin 
negative 
IIIB Troponin 
positive 
IIIC 
 
hr, hours; IAM, myocardial infarction; UA, unstable angina. 
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INFLAMMATORY CELLULAR BASIS IN ATHEROGENESIS 
 
 Atherosclerosis is an inflammatory reaction which occurs due to lipid 
accumulation in the damaged arterial wall.  The science of inflammation in 
atherosclerosis is due to localization of blood leucocytes mainly monocyte and T 
lymphocytes in the earliest lesion.  Generally, when the arterial endothelium is 
normal the blood leucocytes do not bind to the endothelium.  But when they are 
damaged by the atherogenic diet, the arterial endothelium expresses certain 
adhesion molecules like vascular cell adhesion molecule-1 (VCAM-1) and  
(ICAM-1). Fig 6 
 
 
 
 
 
 
 
 
 
Fig. 6. Initiation of atherosclerosis 
 
VCAM-1 binds mainly to monocyte and T-lymphocytes which are found in 
atheromatous plaque.
20,21 
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In the arterial tree there exists a natural protective mechanism, produced by 
the anti-inflammatory property of NO, which are secreted by arterial trees.  This 
decreases the expression of vascular cell adhesion molecules (VCAM-1).
22,23
   
 
However, due to disturbed blood flow and increased stress on the arterial 
wall there increases the expression of selective adhesion molecule and 
proteoglycans that retain leucocytes and lipoprotein particles respectively at the 
site of lesion.
24
 
 
The leucocytes after adhering to the endothelium at the site of lesion 
migrate to the intima with the help of monocyte chemoattractant protein-1 (MCP-
1).
25,26 
This is followed by local inflammatory response by blood derived 
inflammatory cells. Fig 7 
 
 
 
 
 
 
 
Fig 7. Atherosclerosis Progression 
 
Monocyte chemoattractant protein-1 (MCP-1) and macrocyte colony 
stimulating factor are involved in the differentiation of monocytes to 
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macrophages.  These macrophages express receptors for modified lipoproteins 
which engulf lipids and become foam cells. 
27,28
 
 
T Cells elaborate cytokines like lymphotoxin and γ-interferons which 
stimulates macrophage, smooth muscle cells and endothelial cells.
29
 This process 
of inflammation continues and a dense extracellular matrix is laid, which is 
characteristic of advanced atherosclerosis. 
30
 
 
This inflammatory process which is involved in initiation and evaluation is 
also involved in acute thrombotic complication.  Fig 8  
  
 
 
 
 
 
 
 
 
 
Fig 8. Formation of Thrombosis in atherosclerosis 
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Arterial tree endothelial injury(caused by  atherogenic  diet 
 
 
  
 
 
Stasis to blood flow 
             
 
Increases expression of selective 
adhesion molecules on the endothelial 
surface (VCAM-1, ICAM) 
              
 
VCAM-1 binds mainly to monocyte and 
T-lymphocytes. 
              
Move to the intima with the help of 
monocyte chemoattractantprotein-7 
(MCP-1) 
                                  
MCP-1 and MCS differentiate                                                                                  
monocyts to macrophages 
 
Macrophages engulf lipids to form 
foam cells 
Increased stress to blood flow 
 
 
Increased production of proteoglycans 
                                   
 
Retain lipoprotein particles favouring 
and inflammatory response 
                                
Elaborate inflammatory cytokines( γ-
interferon, lymphotoxin) 
 
 Stimulate macrophages vascular 
endothelial  cells,SMC
  
Progression of inflammation 
 
        Contd..
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Release of growth factors and fibrogenic mediators by 
Inflammatory cells 
 
 
 
Elaborates dense extracellular matrix                                                                                  
(more advanced atherosclerotic lesion) 
  
 
 
Acute thrombosis 
 
 
 
Normally collagen renders strength to the plaque and prevents rupture. T 
lymphocytes in the plaque produces γ-interferon which inhibits smooth muscle 
cells from synthesising collagen which in turn decreases plaque formation.  Along 
with this the activated macrophages in the atheroma produces proteolytic enzymes 
which degrade the collagen and renders the cap thin, weak and susceptible to 
rupture.
 31,32
   Macrophages also triggers thrombus formation by producing a tissue 
factor, which is a major procoagulant.  These ruptured atherosclerotic plaque 
causes most of the fatal acute M.I. 
33
 Several mediators or markers of 
inflammation and various sources have been described in (Figure 9).  Table 3 
shows the assay of inflammatory markers, which have potential for clinical use. 
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Fig 9.  Various inflammatory markers release in the circulation during 
inflammation 
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Table 3. Assays of Inflammatory Markers their stability, standards available 
 
Analyte Stability 
Assay 
Availability 
    Standards       
    Available 
Soluble adhesion 
molecules 
( E-selectin,  
 P-selectin, 
ICAM1,VCAM-1) 
Unstable (unless 
frozen) 
Limited No 
Cytokines 
(interleukin-1,6 and 
TNF-α) 
Unstable (unless 
frozen) 
Few Yes 
Acute-phase 
reactants 
 
Fibrinogen 
 
SAA 
 
hs-CRP 
 
 
Unstable (unless 
frozen) 
 
Stable 
 
Stable 
 
 
Many 
 
One 
 
Many 
 
 
Yes 
 
Yes 
 
Yes 
 
WBC count 
 
Stable 
 
Many 
 
Yes 
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PLATELET ACTIVATION AND AGGREGATION 
 
Platelets play a key role in the transformation of a stable atherosclerotic 
plaque to an unstable lesion. Rupture or ulceration of an atherosclerotic plaque 
often exposes the subendothelial matrix (e.g., collagen and tissue factor) to 
circulating blood. The first step in thrombus formation is platelet adhesion via 
platelet glycoprotein (GP) Ib binding to von Willebrand factor and GP VI binding 
to collagen. The ensuing platelet activation leads to (1) a shape change in the 
platelet (from a smooth discoid shape to a spiculated form, which increases the 
surface area on which thrombin generation can occur); (2) degranulation of the 
platelet alpha and dense granules, releasing thromboxane A2, serotonin, and other 
platelet aggregatory and chemoattractant agents; (3) increased expression of the 
GP IIb/IIIa receptor on the platelet surface followed by a conformational change 
of the receptor that enhances its affinity for fibrinogen; and (4) platelet 
aggregation, in which fibrinogen binds to the activated platelet fibrinogen 
inhibitor GP IIb/IIIa, causing a growing platelet plug. 
 
 
SECONDARY HEMOSTASIS 
Simultaneous with the formation of the platelet plug, the plasma 
coagulation system is activated. Tissue factor triggers most coronary artery 
thrombosis. Ultimately, factor X is activated (to factor Xa), which leads to the 
generation of thrombin (factor IIa, which plays a central role in arterial 
thrombosis). Thrombin, which converts fibrinogen to fibrin, is also a powerful 
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stimulant of platelet aggregation and activates factor XIII, which leads to cross-
linking of fibrin and stabilization of the clot. Thrombin molecules are incorporated 
into coronary thrombi and can form the nidus of rethrombosis. 
 
C-REACTIVE PROTEIN 
 
C-Reactive protein was discovered by Tillelt and Francis in 1930.  It was 
first discovered as a substance present in the serum of individuals with acute 
inflammation which reacts with the capsular polysaccharide of pneumococcus.
34 
 
CRP belongs to pentraxin family of calcium dependent legand-binding 
plasma proteins.  The human CRP molecule has five identical nonglyeosylated 
polypeptide subunits.
35  
 Fig 10
 
 
 
 
FIG - 1O.  STRUCTURE OF C-REACTIVE PROTEIN 
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ACTION OF CRP 
 
CRP of human beings binds with phosphocholine residues, autologus and 
extrinsic ligands.  Auto logous ligands include plasma lipoprotein,
36
 damaged cell 
membrane
37
 etc.  Extrinsic ligands include glycan, phospholipid, constituent of 
microorganisms such as capsular and somatic component of bacteria, fungi and 
parasites. When CRP binds with these ligands it is recognised by both classical 
and alternative complement  pathway.
38,39
 The  CRP after binding to ligand 
behaves  like an antibody and contributes to host defence against infection, acts as 
a proinflammatory mediator.  Thus their levels are increased in acute 
inflammation. 
 
 
CRP CONCENTRATION IN CIRCULATION 
The median CRP concentration in healthy individuals is 0.8 mg/l, but 
following acute stimulus the value increases from 50µg/l to more than 500mg/l.
40 
CRP value tends to slightly increase with age. It is a stable compound and shows 
little variation in repeated measurements. There is no significant diurnal variation 
and there is no difference between fasting and non-fasting values. 
 
C reactive Protein is a Strong Predictive Biomarker Why? 
Choosing CRP as a predominant biomarker of cardiovascular events, is due 
to some of its potential advantages over other biomarkers. 
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 CRP has: 
 
 Lack of age and sex dependence·  
 Long half-life of (18 to 20 hours) 
 Lack of its diurnal variation 
 Long-term stability during storage (no special collection procedure)  
 It is also a factor of proatherogenesis 
 
CRPs are produced only by hepatocytes under the control of IL-6 are more 
sensitive and reliable indicator than others like leucocyte count and ESR.  
 
 
CRP Genetics  
 
 The pentameric CRP must undergo structural modification,forming 
monomeric CRP before producing a proinflammatory reaction. Baseline levels of 
CRP show a clear heritability of approximately 40% in studies of families.
41
 
Currently, 3 poly- morphisms in the CRP gene that are associated with changes in 
CRP level.
42
  By identifying genetic variations in the CRP gene, at-risk genotypes 
may be deciphered, providing additional information for overall risk assessment. 
Such genotype-specific risk categories may identify individuals who have 
relatively low serum CRP levels yet display an enhanced proinflammatory 
phenotype. Perhaps these higher-risk individuals will be found to have a 
polymorphism that decreases the stability of the pentameric structure, thereby 
promoting monomeric CRP formation, or alternatively, one that increases the 
stability of monomeric CRP binding to the cell membrane, thereby resulting in 
enhanced endothelial cell activation. (figure11) 
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Figure 11. Changing of Pentameric CRP into Monomeric CRP and 
Producing Inflammatory Reaction 
 
C - reactive protein (CRP) – A mediator in Atherogenesis and endothelial 
dysfunction 
CRP levels correlate inversely with endothelial vasoreactivity.
 43  
The CRP 
acts by decreasing the stability of endothelial nitric oxide synthase (eNOS) m 
RNA.  By inhibiting eNOS , CRP inhibits the release of NO which in turn blocks 
NO dependent angiogenesis.  CRP not only inhibits eNOs but also decreases the 
release of prostacyclin F-1α
44
 which is a stable metabolite of prostacyclin.  It is a 
very potent vasodilator.  It also prevents atherosclerosis by inhibiting platelet 
aggregation and by inhibiting the proliferation of smooth muscle cells.  This C-
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Reactive protein also stimulates superoxide anion (O2
- 
) release which inturn 
inhibits eNOS and PGIs  activity. 
 
It is said that PAI-1 synthesised in the liver, adipose tissue, EC, vascular 
smooth muscle cells and macrophages is a marker of impaired fibrinolysis and 
atherothrombosis and is increased in CAD patients.  Increased expression of PAI-
1 gene on atherosclerotic artery correlates with the increased incidence of 
atherosclerosis and vice versa. 
45
  The CRP induces PAI-1 mRNA  activity in EC. 
Fig12. 
 
Thus it strongly suggests that CRP functions as a procoagulant by                    
a) inhibiting eNOS   b) Prostacyclin   c) Incresed PAI-1 gene expression 
 
 
 
 
 
 
 
 
 
 
 
Figure12.  Mechanism of CRP in atherosclerosis 
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CRP AND MONOCYTE-MACROPHAGES 
 
CRP is proatherogenic in monocyte-macrophage by inducing tissue factor 
secretion,
46
 increases cytokines (IL-1,TNFα,IL-6), increased uptake of oxidised 
LDL 
47
, etc.  CRP has no effect on tissue inhibitor  of metallo proteinase-1 and 
also that CRP  is present in foam cells in the atherosclerotic lesion. Fig 13,14 
 
 
 
 
 
FIG - 13. EFFECTS OF CRP ON VARIOUS CELLS 
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Figure 14. CRP and its association with development of atherothrombosis. 
 
CRP IN ACUTE CORONARY SYNDROME AND STUDIES RELATING TO IT 
 
MI is usually associated with increasing CRP level. CRP falls to normal in 
patients who recover uneventfully with in 3-5 days. The level of CRP remains 
elevated in patients with complications such as persistant cardiac dysfunction, 
aneurysm formation, further infarction,intercurrent infection, thromboembolism. 
European Concerted Action on Thrombolysis and Disabilities study showed that 
the elevation of CRP levels by 20% or more was found in survivors of MI and it 
increases further if other sites, such as peripheral vasculature are involved.
48
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In the study by Liuzzo et al 
49
, it was showed that patients with unstable 
angina and with increased CRP(≥3mg/l) and increased serum amyloidA had 
higher rate of death, acute MI and need for revascularisation surgery compared to 
patients with normal levels. In another study, TIMI  showed that the risk increased 
when the CRP level was high and it presented very early i.e., within 14 days. 
50
 
 
In FRISC study they showed that the level of CRP measurement was 
associated with increase risk.  The CRP level was measured at the time of study 
only.  The risk of coronary events continues to increase throughout for many 
years.
9
 Table 4 
 
Table 4: Studies relating CRP and its association with risk of          
coronary events. 
 
 In a study by R.J. de winter et al said that an abnormal CRP  >0.5mg/l and 
an abnormal TnI (>0.4mg/l) was more in patients with major cardiac events.
51 
 
 P a g e  | 36 
 
Suleiman et al reported that hs-CRP in patients admitted with acute MI is 
predictor of future heart failure and early death.  The CRP also provides 
information about the prognosis in these patients.
52
 Fig 15 
 
 
Figure 15. Incidence of death with respect to CRP
 
 
C.M.Nagesh & Ambuj Roy et al reported. In cases of AMI, CRP release 
is triggered as an acute phase reactant secondary to necrosis and levels of CRP are 
much higher and these have been correlated with infarct size.
1 
A.Dibra et al. 
reported Myocardial salvage was measured by technetium (Tc)-99m sestamibi 
scintigraphy. Patients in the high CRP group had a significantly lower salvage 
index (0.35 ± 0.42 vs 0.48 ± 0.34, p=0.01) and higher 18-month mortality (11.7 vs 
3.2%, p=0.03) compared to those in the low CRP group Fig16 .
53 
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Fig 16 Percentage Of Mortality With Respective CRP Level During 18 
Months Of Follow Up 
  
TIMI 11A study reported that the mortality was high in patients having 
both an early positive rapid cTnT and CRP>1.55mg/dl followed by either of them 
but there is very low risk in patients with both CRP< 1.55mg/dl and a negative 
value of cTnT.
50 
 
Sano et al in their study they included only patients with AMI treated 
within 6 hours of the onset of symptoms. There were no differences in CK-MB or 
Troponin T at admission, which suggests their elevated CRP levels may reflect 
coronary lesions just before rupture but are unlikely to reflect myocardial necrosis.
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It has also been suggested that CRP is elevated in the setting of “active” 
angina and that elevated CRP may be a predictor of a future risk of the onset of 
AMI.  
 
54,55
CRP not only plays an role in vascular inflammation but also in plaque 
rupture. So Serum CRP levels may reflect lesion characteristics in the setting of 
AMI. 
 
De Servi et al, in his study evaluated the cTnT is a sensitive and specific 
marker of myocardial necrosis and is the  best in the prediction of  both death and 
myocardial infarction.  In that study it was also told that the highest values of 
cTnT was associated with mortality only and not with Myocardial infarction.  In 
the same study they reported various values of CRP in Acute Coronary Syndrome 
as CRP level depends on various stimulus.  This explains that why high CRP level 
in ACS is good predictor of death and MI.
56
 
 
RISK STRATIFICATION OF ACS AND hS-CRP 
  
In individuals with ACS, CRP level has been showed to predict adverse 
and future cardiac events.  In many prospective studies it has been reported that 
CRP is a strong predictor of future coronary events among apparently healthy 
women and men.  CRP is an independent risk factor for the cardio vascular 
disease.  CRP as hs-CRP is need  for risk stratification.
4   
In a substudy, GUSTO-
IV, they reported that in patients with ACS both cTnT and CRP were independent 
risk factor for the predicton of mortality, but only cTn was associated with the 
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predicton of MI and that the combination of both CRP and cTnT provided a better 
risk stratification for mortality.
57
  In physician’s health study they measured 
baseline value of CRP, TC, HDL-C and found that individuals with both raised 
CRP and TC subsequently developed their first MI (RR 55.0, P50.0001) than with 
individuals with either increased  CRP (RR 51.5) or TC (RR 52.3). 
58
 Fig 17 
shows various prospective studies relating baseline CRP levels to the risk of first 
cardiovascular events.   
 
Albert and Ridker et al, made a study on hs-CRP and CVD risk prediction 
among women.    
 
Figure 17. Levels of CRP to the cardiac vascular events in different studies 
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National  health and nutrition examination survey 1999-2000 showed that 
hs-CRP level increases with age and also showed that the values of CRP was 
significantly high among women than men and aged>15 years. 
59
 In the same 
study they showed that hs-CRP level was higher in post menopausal women 
taking conventional oral HRT than those who do not. 
60,61
 
 
On admission in patients with unstable angina blood should be drawn for    
hs CRP while admission or at discharge.  Higher level of CRP should be 
considered as high risk for future ischemic events and managed aggressively.  
These include appropriate medical therapy (Statins, Aspirin, ACE inhibitors) and 
also coronary revascularisation in needed.  
 
IN PATIENTS WITH CORONARY REVASCULARISATION 
 
It has been told that CRP levels > 0.3mg/dl before or > 0.5mg/dl at 72 to 96 
hours after the procedure should be closely followed up for ischemic 
complications and late restenosis. 
62
 
 
Clearfield MB et al in their study reported that hs-CRP is an independent 
predictor of  future risk of cardiovascular events among healthy individuals and 
among patients with ACS.  Most of the cardiovascular events occured in patients 
with low to average level of LDL cholesterol.  In these  patients  also hs-CRP aids 
as a predictor of first cardiovascular events which would be missed by lipid 
screening alone.  Thus hs-CRP  is a potential adjunct for global risk assessment 
in the primary prevention of cardiovascular disease.
63
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Rifai and Ridkar et al in their study reported hs-CRP is a strong and 
independent predictor of future coronary events in apparently normal individuals 
and also has a progonostic utility in patients with ACS. 
4  
Fig 18 
 
 
 
Fig. 18. RR Of Future Cardiovascular Events With Respect To Various 
Biochemical Markers. 
 
Speidl WS, Graf S et al reported that CRP level > 1.6mg/l in individuals 
with < 50 years , who are clinically stable and have  a positive history of acute 
coronary symptom, indicates future risk of coronary events.  This also indicates an 
ongoing inflammatory process.
64 
 
Paul M Ridker et al reported that the baseline levels of CRP and LDL 
cholesterol each had  a strong linear relation with the incidence of cardiovascular 
events.
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In a separate analysis for each component of the end point among users and 
nonusers of HRT among women. 77% of all events occurred in patients with LDL 
< 160 mg/dl and 46% among LDL < 130 mg/dl.  But, by screening, both CRP and 
LDL provides a better prognostic information than either alone.  Independent 
effects were also observed for CRP.  These suggest that CRP is a strong predictor 
of cardiovascular events.
65 
Fig 19
 
 
C.M. Nagesh and Ambuj Roy et al, reported association of CRP and 
ACS. It is important to distinguish cases without (unstable angina) and with 
necrosis (acute MI). In cases of AMI, CRP release is triggered as an acute phase 
reactant secondary to necrosis and levels of CRP are much higher and these have 
been correlated with infarct size. Mortality has been shown to be related to CRP 
levels independent of left ventricular systolic function. In the absence of 
infarction, CRP levels correlate to the extent of atherosclerosis and shown that it 
predicts coronary events in patients of unstable angina independent of troponin 
levels.
1 
 
 
 
 
 
 
 
 P a g e  | 43 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 19. Comparison between CRP and LDL Cholesterol in Probability 
of Event Free Survival 
 
 
STRUCTURE OF TROPONIN 
 
Troponin is a complex of three regulatory proteins (troponin C, troponin I 
and troponin T) that is integral to muscle contraction
 
 in skeletal and cardiac 
muscle (fig20) but not smooth muscle. Troponin is attached to the protein 
tropomyosin and lies within the groove between actin filaments in muscle tissue. 
In a relaxed muscle, tropomyosin blocks the attachment site for the myosin 
crossbridge, thus preventing contraction (fig21). When the muscle cell is 
stimulated to contract by an action potential, calcium channels open in the 
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sarcoplasmic membrane and release calcium into the sarcoplasm. Some of this 
calcium attaches to troponin which causes it to change shape, exposing binding 
sites for myosin (active sites) on the actin filaments. Myosin binding to actin 
forms cross bridges and contraction (cross bridge cycling) of the muscle begins. 
Troponin is found in both skeletal muscle and cardiac muscle, but the specific 
versions of troponin differ between types of muscle. The main difference is that 
the TnC subunit of troponin in skeletal muscle has four calcium ion binding sites, 
whereas in cardiac muscle there are only three. Both cardiac and skeletal muscles 
are controlled by changes in the intracellular calcium concentration. When 
calcium rises, the muscles contract, and when calcium falls, the muscles relax. 
Troponin is a component of thin filaments (along with actin and tropomyosin), 
and is the protein to which calcium binds to accomplish this regulation. Troponin 
has three subunits, TnC, TnI, and TnT. When calcium is bound to specific sites on 
TnC, tropomyosin rolls out of the way of the actin filament active sites, so that 
myosin (a molecular motor organized in muscle thick filaments) can attach to the 
thin filament and produce force and/or movement. In the absence of calcium, 
tropomyosin interferes with this action of myosin, and therefore muscles remain 
relaxed.
66 
 
Individual subunits serve different functions: 
1. Troponin C binds to calcium ions to produce a conformational change in 
TnI. 
 
2. Troponin T binds to tropomyosin, interlocking them to form a troponin-
tropomyosin complex. 
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3. Troponin I binds to actin in thin myofilaments to hold the troponin-
tropomyosin complex in place.  
 
Though troponin is found both in skeletal and cardiac muscles, the high 
specificity depends on the unique peptide sequence of cardiac troponin which is 
absent in skeletal muscle troponin.  
 
TnI Is a 24 KD protein that maintains a 40% structural distinction from the 
skeletal Troponin I isoforms.
67,68,69
 TnT is a 37 KD protein that is 10-
30%dissimilar from skeletal troponin T isoforms.  Following myocardial damage, 
TnT and TnI are released in different forms. 
 
 
 
 
 
 
 
 
 
 
Fig 20.  CTnT in calcium-saturated  form. 
Blue = troponin C       green = troponin I      magenta = troponin T 
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Fig 21 Troponin  in activated and inhibited state 
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CARDIAC TROPONIN IN ACUTE CORONARY SYNDROME 
 
 Cardiac troponin which is structurally different from skeletal troponin has 
been very useful in the differentiation of MI from other causes of chest pain.  
Troponin T is a contractile protein that is normally not present in serum.  It is 
released only when myocardial necrosis occurs.  There are many cardiac 
biomarkers like CK-MB, myoglobin, cardiac troponin, but cardiac troponin are the 
more sensitive and specific for detection of even a minor amount of myocardial 
damage. (Table 5)  
 
Enzyme Marker Discription Source 
Cause Of 
Increase 
Cardiac 
Troponins 
Contractile Protein 
Complex 
Two Isoforms 
I And T 
Heart Injury To Heart 
Ck-Mb 
Isoenzymes 
Related To 
Myocardium 
Primarily 
Heart,Skeletal 
Muscle Also 
Injury To Heart 
And Skeletal 
Muscle 
Myoglobin 
Oxygen Storing 
Proteins 
Heart And Skeletal 
Muscle 
Injury To Heart 
And Skeletal 
Muscle 
 
Table 5 Cardiac Biomarkers: description source and reason for increase 
A large number of studies have shown that cardiac troponin are “the gold 
standard” for diagnosis of acute MI.   
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 There are evidence based on studies supporting that cardiac troponin has a 
role both in the diagnosis of MI and for post infarct risk assessment.  Current 
guidelines from the European Society of Cardiology (ESC), American College of 
Cardiology (ACC) and American Heart Association (AHA) state that Cardiac 
troponin  is the preferred marker for MI diagnosis, particularly in the absence of 
clear ECG evidence.  NSTEMI patients usually present with normal ECG or 
inconclusive ECG irregularities like T-wave inversion or ST depression.  In 
myocardial necrosis (ischemia induced and others) there increases the release of 
cardiac troponin contained in the cell cytosol.  Usually the cardiac troponin is 
detected in the serum   6 hours after infarction and the peak usually at 12-24 hours 
and then return to normal by 7-14 days of infarction.  The persistence of cardiac 
troponin is due to secondary degradation of myofibrils. Fig 22  
 
  
Fig 22 
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As the cardiac troponin rises only after 6 hours and when  the patients are 
unable to say the time of onset of symptoms, it would be difficult to assess the 
single sample if taken before 6 hours of onset of MI (Table 6). A second sample 
should be collected 6-12 hours post presentation. 
70,71 
 
 
Enzyme 
Marker 
Time Of 
Increase 
Remain 
Elevated 
Till 
Sensitivity Specificity Assay 
Cardiac 
Troponin 
3-4 Hrs 
After 
Injury 
7-14 Days High High 
cTnT - One 
 
cTnI - Many 
CK-Mb 
4-6 Hrs 
After 
Injury 
48-72 Hrs 
Less Than 
Cardiac 
Troponin 
Less Than 
Cardiac 
Troponin 
- 
Myoglobin 
2-4 Hrs 
After 
Injury 
24 Hrs High Poor - 
 
Table 6 
 
Katus et al, reported that cTnT has high efficacy (94%) when compared to 
creatine kinase (63%) in detecting cardiac damage. 
72 
 
C.M. Nagesh and Ambuj Roy et al, reported   Cardiac troponin is a well 
established biomarker for diagnosis and prognosis of ACS .
1 
The data for 
troponins in ACS is robust even at minimally elevated levels. Cardiac troponins  
are now very useful in the diagnosis of MI.
73 
With current high quality analytic 
methods, cardiac troponin measurements are highly sensitive and specific for 
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myocardial injury .
74
 In the appropriate clinical setting (high certainty that the 
troponin is due to acute coronary syndrome) even minor elevations of troponin 
identify high risk underlying coronary morphology like patients with plaque 
rupture, large thrombus burden and distal embolisation.
75 
These patients clearly 
benefit from aggressive anti-platelet, antithrombotic and revascularization therapy 
. cTn typically increases more than 20 times above the upper limit of the reference 
range in myocardial infarction as compared to creatine  kinase myocardial  band 
(CK-MB) which usually increases 10 times above the reference range. The cTn 
begins to elevate 3 h from the onset of chest pain in MI. Because of the continuous 
release, cTn elevation persists for days (cTnI: 7-10 days, cTnT: 10-14 days). This 
prolonged course of release with troponin is very useful in the late diagnosis of 
MI, However, it limits the diagnosis of early reinfarction.  However, the important 
advantage of cTnT is that due to international patent restrictions there is only one 
assay for its measurement.
76 
Thus measuring cTnT is more advantageous than 
cTnI as troponin I has 18 different commercial assays and different cut off 
concentrations. 
 
RISK STRATIFICATION OF TROPONIN-T IN ACS 
Ischemic heart disease has a wide range which includes silent ischemia and 
progresses to acute MI.  The gold standard for the diagnosis are the cardiac 
specific bio markers which include CKMB, Troponins.  Initially CK-MB was used 
for the diagnosis of MI and was proposed as a component of diagnostic criteria by 
WHO.
77
 This elevated CK-MB not always detects MI. Sometime death suddenly 
occurs in patients with silent MI.  In these patients CKMB may be negative but at 
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atopsy micro necrosis may be revealed. This leads to the measurement of   better 
cardiac marker like cTnT and cTnI, which has high specificity and sensitivity for 
myocardial damage.
78 
Troponins are the biomarkers which identify myocardial 
micronecrosis which may not be diagnosed by conventional definition.
79,80
  
American College of Cardiology/American Heart Association guidelines for 
management of NSTE ACS, included measurement of Troponins as a basic 
investigation in the diagnosis of NSTEMI.  Troponin was also involved in the risk 
identification. 
 
The Troponins (T&I) have similar release mechanism.  In the serum both 
are detected at about 4-12 hours and peaks around 12 to 48 hours and remains 
elevated for about 7-14 days.  Thus they are useful even when the patient is 
delayed for presentation after symptom onset. 
81
 
 
 
CARDIAC SPECIFIC TROPONIN AS PROGNOSTIC INDICATOR IN 
NSTE-ACS 
 
Patients who have chest pain with normal ECG are considered as important 
individuals, as there are more chances to miss them than those who have elevated 
ST changes in ECG.
82
 As myocardial necrosis is an important prognostic indicator 
83
, early identification of patients  with  MI becomes  essential for Initial  triage 
decision and initiation of treatment.   
 
In FRISC study they showed that there was a strong correlation between 
troponin elevation and 30-days mortality.
84
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Thrombolysis is myocardial infarction (TIMI) IIIB investigators reported 
that cTnI elevation was directly proportional to the risk of mortality in patients 
with UA.  This result was found in 42 days study.
85
 
 
(GUSTO)-IIB investigators in their study found that troponin T was a 
powerful marker of short term mortality risk. 
86
 This leads to the measurement of 
troponin in prediction of MI in non –ST elevation patients. 
87
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SUMMARY 
The pathogenesis of atherosclerotic heart disease is not simply due to lipid 
deposition but inflammation has a key role in endothelial damage.  Acute phase 
reactants which are non-specific markers of inflammation and elevated in all 
stages of atherosclerotic heart disease. Among them hs-CRP measurement appears 
to be highly specific.  It predicts long term risk of mortality in patients of ACS.    
HsCRP when combined with cTnT a cardiac specific biomarker gives a high 
predictive value of myocardial necrosis than when measured alone.  Elevated 
serum cTnT in patients with ACS is associated with increased incidence of MI and 
death. Previous studies reported the increased CRP even with negative cTnT had 
worse clinical outcomes.  These include mortality and prolonged hospitalisation. 
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MATERIALS & METHODS 
Study population: 
The study was conducted among patients admitted with ACS of 
UA/NSTEMI in the emergency Department and ICCU of Cardiology Department 
in Kilpauk Medical College Hospital, Chennai. 
 
Study type  
It is a Prospective study 
 
 Study period:  
Data collection was done from September 2011 and August 2012. 
 
Base line assessment: 
A detailed medical history regarding risk factors like-diabetes mellitus, 
hypertension, smoking, obesity, dyslipidemia, H/O previous CABG or PTCA, 
H/O stroke, H/O peripheral vascular disease and family history of premature 
coronary artery disease; as well as previous symptoms such as pre infarction 
angina were obtained. Full physical examination was done in all patients. Blood 
sugar, urea, serum creatinine, lipid profile level were obtained. Serum level of 
hsCRP and cTnT was measured 6hrs after admission in all patients. Any evidence 
of the presence of an obvious source of infection, either by clinical assessment or 
laboratory investigations served as basis for exclusion from the study. 
 
 P a g e  | 55 
 
Definition:  
Death was defined as all-cause mortality. 
Unstable angina or NQMI defined as angina pectoris (or equivalent type of 
ischemic discomfort) with at least one of three features: (1) occurring at rest (or 
minimal exertion) and usually lasting >20 minutes (if not interrupted by the 
administration of a nitrate or an analgesic); (2) being severe and usually described 
as frank pain and of new onset (i.e., within the prior 4–6 weeks); and/or (3) 
occurring with a crescendo pattern (i.e., pain that awakens the patient from sleep 
or that is more severe, prolonged, or frequent than previously). The diagnosis of 
NSTEMI is established if a patient with the clinical features of UA develops 
evidence of myocardial necrosis, as reflected in elevated cardiac biomarkers. To 
support the presence of ischemic heart disease, patients must have met at least one 
of the following criteria: a history of typical myocardial ischemic-type discomfort; 
electrocardiographic changes (ST-segment depression of at least 0.5 mm 
,persistent negative T wave over the involved area ,Deeply negative T waves 
across all the precardial leads ) in association with ischemic discomfort; a history 
of previous myocardial infarction (MI);  previous coronary artery bypass graft 
surgery (CABG) or percutaneous transluminal coronary angioplasty.  
 
New MI during current hospitalization was defined as a new episode of 
prolonged chest pain, resistant to nitrates, with new electrocardiographic changes 
of ST-T changes and an increase in the plasma cTnT level and CKMB level at 
least three times the upper limit of normal value.  
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Inclusion criteria:  
All Patients admitted with unstable angina and NSTEMI in the Emergency 
department and ICCU of the cardiology department in Kilpauk Medical College 
hospital.  
 
Exclusion criteria:  
 Active infection  
 Chronic inflammatory disease,  
 hepatic dysfunction, 
 Renal dysfunction, 
 Malignancy,  
 Major surgery in the previous 1 month,  
 Peripheral arterial disease, 
 Metabolic syndrome, 
 Patients with ST elevation MI and Thrombolysed within 48 hours, 
 Trauma, 
 CABG within the previous 2 months. 
 
Laboratory methods of measuring hs-CRP:  
Quantitative determination of hsCRP is done by COBAS-C systems of 
Roche diagnostics USA. hsCRP is measured by particle enhanced immune-
turbidimetry assay. Human CRP agglutinates with latex particles coated with 
monoclonal anti-CRP antibodies. The precipitate is determined turbid metrically. 
Reagents used are R1-TRIS buffer with bovine serum albumin and 
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immunoglobulins (mouse), R2-Latex particles coated with anti-CRP (mouse) in 
glycine buffer.  
  
Laboratory methods of measuring cTnT:  
Quantitative determination of CTnT is done by Cobas-e 602 analyser of 
Roche diagnostics USA, based on sandwich principle. Total duration of assay is 9 
minutes. During a 9 minutes incubation, antigen in the sample,a biotinylated 
monoclonal troponin T- specific antibody, monoclonal troponin T- specific 
antibody labelled with a ruthenium complex and streptavidin- coated micro 
particles react to form a sandwich complex, which is bound to solid phase. 
 
The reaction mixture is aspirated in to the measuring cell where the micro 
particles are magnetically captured on to the surface of the electrode. Unbound 
substances are then removed with Procell. Application of voltage to the electrode 
then induces chemiluminescent emission which is measured by a photo multiplier. 
Results are determined via a calibration curve which is instrument –specifically 
generated by 2-point calibration and a master curve provided via the reagent 
barcode. 
 
Laboratory methods of measuring CKMB: 
CKMB was measured by Cobas-e analyser by Roche diagnostics USA 
based on sandwich principle.  During a 9 minutes incubation, antigen in the 
sample, a biotinylated monoclonal anti-CKMB antibody, monoclonal CKMB - 
specific antibody labelled with a ruthenium complex and streptavidin- coated 
microparticles react to form a sandwich complex, which is bound to solid phase. 
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The reaction mixture is aspirated in to the measuring cell where the micro 
particles are magnetically captured on to the surface of the electrode. Unbound 
substances are then removed with Procell. Application of voltage to the electrode 
then induces chemiluminescent emission which is measured by a photo multiplier. 
Results are determined via a calibration curve which is instrument –specifically 
generated by 2-point calibration and a master curve provided via the reagent 
barcode. 
 
 
STATISTICAL ANALYSIS 
 
 The data obtained were maintained in the master chart in Microsoft Office 
Excel format.  The statistical analysis was done using SPSS 20
th
 version. hs-CRP 
and cTnT were measured 6 hours after admission as cTnT raises only about 4-6 
hours after the onset of symptoms. 
 
The values of CRP were divided into quintiles, quartiles.  cTnT was taken 
as positive (>0.01µg/l) and negative (<0.01µg/l).  For continuous variables means 
were expressed with one standard deviation. For the outcome of death and 
subsequent MI at 14 days a 2X2 table was constructed and sensitivity, specificity 
and likelihood ratio for each test was determined. All statistical significance was 
defined as a p value < 0.05 using chi square test. 
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RESULTS 
 
Initially we recruited 122 patients in our study.  But 26 patients did not 
come for review.  So finally 96 patients were taken for our study. Out of them 
60(62%) were males and 36(38%) were female (Chart1&2). Among them 
55(57.3%) had HTN and 40(41.6%) patients had diabetes. 23(24%) patients had 
both HTN and diabetes.  ECG changes in 85(88.5%) patients.  50(52.08%) 
patients had previous history of Angina.  3(3.1%) had past history of MI and 
4(4.16%) had previous CABG done. 
 
 
 
 
 
 
 
 
 
 
Chart1.Age distribution of coronary artery disease patients 
 
Higher incidence of CAD was found in patients between 50-70 years 
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Chart - 2. Sex distribution 
 
 We measured hsCRP and cTnT 6 hours after admission for all patients.  
Range of hsCRP obtained was 0.1mg/lt to 17.11mg/lt (median 0.76mg/lt).  Among 
them patients with hsCRP >3mg/lt were 30(31.25%).  cTnT was positive in 16 
patients (16.5%). These patients baseline characteristics are shown in Table 7.  
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Table - 7 (Base Line Characteristics) 
Base line characteristics 
CRP <3mg/l 
(N=66) 
CRP >3mg/l 
(N=30) 
Mean age (yr) 56.91 58.7 
Male 42 (70%) 18 (30%) 
Female 24 (66.6%) 12 (33.3%) 
Mean Weight (KG) 67 67 
Diabetes 24(60%) 16 (40%) 
Current smoker 14(56%) 11(44%) 
Hypertension 40(72.8%) 15(27.2%) 
Previous Angina 34(68%) 16(32%) 
MI 1 2 
CABG 1 3 
PTCA 
 
1 0 
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 In our study  it  showed  that  there is a positive correlation between  
a) BMI and increasing quintiles of hsCRP,   
b) DM and increasing quintiles of hsCRP,   
c) LDL>130mg/dl and increasing quintiles of hsCRP. It also showed a 
negative correlation with HTN and no relationship was found 
between hsCRP and previous angina. Charts 3,4,5,6,7   
 
 
 
 
 
 
 
 
 
 
 
 
CHART 3.BMI WITH RESPECT TO INCREASING QUINTILES OF CRP 
  
BMI>25kg/sq.m is considered as over weight and is supposed to be a risk 
factor for CAD.  
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CHART 4.DIABETES MELLITUS WITH RESPECT TO INCREASING 
QUINTILES OF CRP 
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CHART 5.  LDL >130 Mg/dl WITH RESPECT TO INCREASING 
QUINTILES OF hSCRP 
 
 
There were 6,9,10,11,11 patients who had LDL>130 mg/dl in 1
st
, 2
nd,
 3
rd
, 
4
th
, 5
th
 quintiles respectively. This showed a positive correlation.  
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CHART 6. HYPERTENSION AND INCREASING QUINTILES OF hSCRP 
 
 
 
CHART 7.PREVIOUS ANGINA AND CRP 
Previous angina showed no relation with hsCRP in our study. 
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All the patients included in the study received inj.Heparin, aspirin, 
clopidogrel, ACE inhibitor, Statins, nitrates and Beta blockers by ruling out their 
specific risk factors. 14 days follow up was made.  While in the hospital stay 5 
patients died.  Among them 4 were males and 1 female patient. 1 death was due to 
Arrythmia, 3 deaths were due to cardiogenic shock, 1 death due to Non cardiac 
cause.  
  
5 patients had subsequent ST elevation MI during hospitalisation.  Among 
them 3 were males and 2 females.  One male patient was readmitted for MI within 
14 days of study.Thus totally 6 persons developed MI during the study period. 
 
 
Association of cTnT with CRP 
 
Out of 96 patients included in the study 80 patients had negative cTnT and 
16 patients had positive cTnT.   The positivity of cTnT was taken as cTnT value 
>0.01µg/l. The percentage of patients with positive cTnT increased with 
increasing concentration of hs-CRP. 
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CHART - 8 
N=96   Percentage of patients with positive cTnT in each quintile of CRP 
concentration 
 
The median value of CRP was 0.76 mg/l.  5% of the patients with positive 
cTnT were in the Ist quintile, 5% in 2
nd
 quintile, 15% in the 3
rd
 quintile, 22% in 
the 4
th
 quintile and 36% in the 5
th
 quintile of CRP. Chart 8 
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Association of Serum Markers with Clinical Outcomes 
CRP and Mortality 
 
CHART 9.FREQUENCY OF HSCRP IN OUR STUDY GROUP 
 
CRP values were divided into four quartiles.  (<0.50mg/l, 0.51-0.76mg/l, 
0.77-6.58mg/l and >6.58mg/l)  The all cause mortality within 14 days among the 
patients (study group) was 5.2%.  Mortality was higher among patients with 
CRP>3mg/l than others (chart 9).  In the study population of 96 patients, 5 
patients died and among them 4 patients had hs-CRP > 3 mg/l. 
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CHART 10. No OF DEATH IN EACH QUARTILE OF CRP 
 
 
hsCRP <0.50 0.51-0.76 0.77-6.58 >6.58 P value 
Mortality 1 0 2 2 .001 
 
Table 8. MORTALITY WITH RESPECT TO CRP AND ITS P VALUE. 
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HsCRP (mg/L) * Death during Hospitalisation 
 
 Value df 
Asymp. Sig. (2-
sided) 
 
Pearson Chi-Square 
42.831
a
 17 .001 
 
Likelihood Ratio 
 
21.606 17 .200 
No of Valid Cases 96   
 
TABLE - 9 
Table 8 and 9 shows the mortality with respect to CRP values and its P value is 
calculated as 0.001. 
 
 
CTnT and Mortality and comparison with CRP 
Among the 5 patients, who died, 3 patients had positive cTnT(>0.01µg/l) 
18% and 2 negative cTnT (<0.01µg/l), P value = 0.008 (Chart 11) 
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CHART 11. MORTALITY WITH RESPECT TO cTnT 
 
 
CTnT Positive >0.01µg/l Negative <0.01µg/l 
Mortality 3 2 
 
TABLE  10. MORTALITY WITH RESPECT TO cTnT 
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CTnT(mg/L) * Death during Hospitalisation 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 7.131
a
 1 .008   
Continuity 
Correction
b
 
4.220 1 .040   
Likelihood Ratio 5.136 1 .023   
Fisher's Exact Test    .031 .031 
No of Valid Cases 96     
 
TABLE 11 
 
Table 10&11 Shows the Mortality with respect to CTnT and P value (0.008) is 
calculated using chi-square test. 
 
 
3 patients, who died, had positive cTnT also had CRP>3mg/l.   The 
mortality rate of cTnT positive group with CRP<3mg/l was 0% when compared 
with CRP>3mg/l was 19%.  Stratifying by both hsCRP and cTnT, we found that 
a) Mortality was high among patients with both CRP >3 mg/l and cTnT positive   
b) Followed by either CRP> 3 mg/l or cTnT positive and   c) Low risk was found 
in patients with negative cTnT and CRP< 3 mg/l. Chart 12.      
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Yellow bar- hsCRP<3mg/l 
blue bar-hsCRP>3mg/l 
CHART- 12. MORTALITY AT 14 DAYS BY COMPARING                       
hsCRP AND cTnT 
 
Cardiac Markers and MI 
Among the 96 patients who were taken into the study 6 patients developed 
subsequent MI (6.25%) . 5 (5.20%) of them developed MI while in the hospital 
stay itself and 1 patient was discharged on the 10
th
 day and was readmitted in the 
hospital on the 12
th
 day from the date of first episode of MI. The subsequent MI in 
this patient was confirmed by ECG changes and also by CK-MB elevation. 
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hs-CRP and MI 
 
CHART -13. OCCURRENCE OF MI WITH RESPECT TO hSCRP 
 
 
hsCRP <0.49 0.50-0.76 0.77-6.58 >6.58 P value 
MI 1 0 3 2 0.061 
 
TABLE.-12 MI WITH RESPECT TO CRP AND P VALUE CALCULATED 
BY CHI-SQUARE TEST 
 
 P a g e  | 75 
 
Among the 6 patients who developed subsequent MI after admission for 
ACS, only 3 patients had hs-CRP > 3 mg/l.  The CRP values were diveded into 
quartiles and the occurence of MI was plotted into the quartile and we found that 1 
case occured in first quartile(1.04%), 0 in second quartile(0%), 3 in third 
quartile(3.12%) and 2 in the fourth quartile(2.08%).P value = 0.061, which is 
insignificant. (Chart 13), TABLE 12.  
 
cTnT and MI 
5 patients who developed subsequent MI while admission and one patient 
who was readmitted for MI diagnosed  by elevated CKMB and ECG changes  (6 
patients) all had cTnT positive(>0.01µg/l) (100%).  This showes that there is very 
strong association between MI and cTnT positivitiy. (Chart 14), Table 13. 
 
CHART 14. MI WITH RESPECT TO cTnT 
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cTnT Positive Negative P value 
MI 6 0 0.0001 
 
TABLE 13. P VALUE CALCULATED BY CHI-SQUARE TEST 
 
 
COMBINATION OF CTNT AND CRP 
With respect to Mortality in ACS patients study group 
During our study period of 14 days, the all cause mortality among 96 
patients was 5 (5.21%).   When mortality was taken into account  the rate of its 
occurence in the study group increases with increase in the value of hs-CRP.  We 
found that the rate of mortality was more among patients with hs-CRP > 3 mg/l 
(4.16%) when compared to CRP < 3 mg/l (1.04%).  Chart 15. 
 
Chart 15. Mortality and hsCRP 
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Similarly, when cTnT is taken into account , 3 patients had positive  cTnT 
> 0.01 µg/l i.e., 3.12% and 2 patients had cTnT(<0.01 µg/l) negative i.e., 2.08%.  
This showed that cTnT is also a good predictor of occurrence of mortality in 
patients with ACS. P value 0.008. 
 
While comparing both markers with mortality, 3 patients had both 
CRP>3mg/l and also cTnT positive (3.15%), 1 patient had CRP alone > 3 mg/l but 
cTnT negative  (1.04%) and 1 patient had CRP < 3 mg/l and cTnT negative 
(1.04%).  This clearly shows that the rate of death among patients with acute 
coronary syndrome is low when both the markers are below the normal values 
(CRP < 3 mg/l and cTnT negative)   (01.04%) and the rate of occurrence of death 
increases when both the markers are above the normal acceptable limits. (CRP >3 
mg/l and cTnT positive) (3.12%) Table 14. 
 
Bio marker 
hsCRP>3mg/l & 
cTnT positive 
hsCRP>3mg/l or 
cTnT positive 
hsCRP<3mg/l or 
cTnT negative 
Mortality 3 1 1 
 
Table - 14.  Biomarkers and mortality 
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Bio marker cTnT positive hsCRP>3mg/l 
hsCRP>3mg/l & 
cTnT positive 
Sensitivity 60% 80% 30% 
Specificity 97.5% 98% 97.5% 
 
 
Table 15.  This table gives the Sensitivity  and Specificity of the biomarkers 
with respect to mortality 
 
 
With Respect to Subsequent MI after the Admission 
During the study period, taking the occurrence of subsequent MI after 
admission into account, we found that among the 6 patients all the 6 patients had 
cTnT positive.  (> 0.01 µg/l) but only 3 of them had CRP > 3 mg/l.  We also found 
that there was a decline in the rate of occurrence of subsequent MI in the fourth 
quarter of hsCRP.  These findings clearly show cTnT had a very strong 
association with occurrence of MI in acute coronary syndrome.  However there 
was no relationship between the rate of occurrence of subsequent MI and 
increasing quartile of hs-CRP 1.01%, 0%, 3.12% and 2.1% respectively.      
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DISCUSSION 
 
Acute Coronary Syndrome is a disease of inflammation which is associated 
with increase in serum biomarkers.  Our study was designed to predict the 
association of hs-CRP and cTnT in Unstable/NSTEMI patients with the 
occurrence of subsequent MI and death in 14 days after admission in ICCU and 
Emergency ward.  Of the total 96 patients, 5 (5.20%) died while in hospital and 6 
(6.25%) patients developed subsequent MI during the study period. 
 
In our study 60 were male patients and 36 female patients.  The mean age 
of occurrence of ACS in male was 57.36 years and in female was 57.28 years.  18 
(30%) males with ACS had hs-CRP> 3 mg/l and 12(33.3%) females with ACS 
had hs-CRP > 3 mg/l. 
 
In our study, a high hs-CRP level  > 3 mg/l was found to be significantly 
associated with mortality with in 14 days with sensitivity   80%,   specificity   98% 
and p value .001  and the elevated CRP had no relation with the occurrence of MI 
with a p value of 0.061. Our study is in agreement with GUSTO IV and Scirica et 
al where the blood sample for hs-CRP was drawn at serial intervals 8,16,24 and 48 
hours and on admission respectively.  In GUSTO IV
65
 in a 30 days study, with 
increasing quartiles of CRP there was increase in the rate of mortality p(0.001) but 
the rate of occurrence of subsequent MI had no relation with increasing CRP.  In 
Scirica et al 
88
 reported the same that CRP > 15 mg/l on admission had increased 
rate of short term and long term mortality (p<0.001) and also that increased CRP 
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had no association with the occurrence of rate of short term and long term MI 
(p=0.09 and 0.54 respectively). Our study was in partial agreement with Liuzzo et 
al, TIMI 11A, Ernest.R. Ferriero et al.  In Liuzzo et al,
49
 blood sample was 
collected at the time of admission and they reported that hs-CRP > 0.3 mg/dl  was 
associated with increased incidence of ischemic episodes, MI, death while hospital 
stay ( p= 0.004).  In TIMI 11A,
50
 they reported CRP > 1.55 mg/dl had a strong 
association with the rate of occurrence of mortality within 14 days with a 
specificity of 76% and sensitivity 86%. Ernest R.  Ferriero et al
89
 collected 
sample for hs-CRP 3 times ( on admission, after 48 hours and at discharge).  They 
reported that the value of hs-CRP >1.5 mg/dl at discharge had a Strong correlation 
with the rate of occurrence of MI, angina, mortality at 90 days (P=0.0001). 
 
STUDY 
MEASUREMENT OF 
hsCRP 
CONCLUSION 
Liuzzo et al
49
 At the time of admission 
>0.3 mg/dl associated with more 
ischemic episode, MI, death while 
in hospital stay(p=0.004) 
TIMI 11A
50
 6 hours after admission. 
>1.55 mg/dl was associated with 
increased mortality with 
sensitivity 86% and specificity 
76% (p=0.001) 
GUSTO IV
65
 
Blood sample collected at 
8,16,24,36 and 48 hours 
a) Increasing quartile of CRP 
associated with increasing rate of 
mortality (p=0.001) at 30 days.                                        
b)  not related to occurrence of MI 
at 30 days (p=0.4) 
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Ernest Ferriero  
et al
89
 
Measured on admission, 48 
hours and while discharged 
CRP > 1.5 mg/dl at discharge was 
a strong independent marker of 
combined end point of MI or 
death on 90 days (p=0.0001). 
Scirica et al
88
 Immediately on admission 
Hs-CRP > 15mg/l associated with 
increased mortality at 30 and 90 
days (p<0.001), not associated 
with recurrent MI (p=0.09 and 
0.54 at 30 and 90 days 
respectively) 
Our study 6 hours after admission 
Hs-CRP >3mg/l was associated 
with increased mortality on 14 
days study with sensitivity 80%                             
and specificity 90% p=0.001and 
not associated with occurrence of 
subsequent MI (p=0.061) 
 
We also found that cTnT positivity (>0.01 µg/l) is also an important 
predictor of occurrence of subsequent MI and death within 14 days of study 
period. P value < 0.0001, 0.008 respectively. Our results are in agreement with 
various studies. TIMI 11A
50
,  in which blood for cTnT was collected 6 hours after 
admission and they reported that in their14 days study, a rapid positivity of cTnT 
i.e., appearance of red line in the test kit within 10 minutes was associated with 
increased mortality than with late cTnT positivity in   patients with Acute 
Coronary Syndrome ( sensitivity 29%, specificity 79%).  In GUSTO IV 
65
 the 
blood sample was collected at serial intervals of 8,16,24,36 and 48 hours.  They 
carried out the test for 30 days and reported that increasing quartiles of cTnT was 
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associated with increased mortality and subsequent MI in ACS (p  < 0.001).  In 
FRISC II
57
 substudy blood was collected with a median time of 38.6 hours and 
reported that positive cTnT was associated with increased risk of reinfraction (p < 
0.001) and increased risk of death (p < 0.001) in ACS.  In Robert H. 
Christenson
90
 blood sample for cTnT was collected 3.5 hours after admission and 
showed that there was a strong association between positive cTnT and death (p < 
0.001) and with early MI (p <0.0001) in ACS, than with late MI (p=0.125).  In 
Solymoss BC
91
 cTnT was measured within 6 hours after the onset of chest pain 
and reported that positive cTnT was associated with nonfatal MI and death within 
48 hours (p<0.001).  
 
STUDY 
TIME OF 
MEASUREMENT cTnT 
CONCLUSION 
TIMI 11A
50
 6 hours after admission 
Rapid cTnT positive individuals 
have increased mortality  
Sensitivity 29% 
Specificity 79% 
GUSTO IV
65
 
Blood sample collected at      
serial intervals 
Associated with increased 
mortality and MI with 
increasing quartiles of cTnT 
(p<0.001) 
FRISC II 
SUBSTUDY
57
 
With median of 38.6 hours 
Increased risk of reinfarction 
(p<0.001) 
Increased risk of death 
(p<0.001) 
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Rober H 
Christenson
90
 
3.5 hours after admission 
a)cTnT showed strong 
association with death (p<0.001) 
b)showed strong association 
with early MI than with late 
MI(p<0.0001) 
Solymoss BC
91
 
Within 6 hours after the 
onset of chest pain 
Elevated cTnT was associated 
with nonfatal MI and death 
within 48 hours (p<0.001) 
Our study After 6 hours of admission 
Positive cTnT was associated 
with increased mortality 
(sensitivity 60% and specificity 
97.5%) (p=0.008) and with 
increased nonfatal MI 
(P=0.0001). 
  
 
Our study has showed that hs-CRP>3 mg/l in ACS patients was associated 
with increased risk of mortality with the sensitivity of  80% and specificity 98% 
and p value of 0.001(significant). At the same time our study showed that the 
higher value of hs-CRP had no relationship with the occurrence of subsequent 
myocardial infarction P=0.061(not significant).  When cTnT was taken as a 
marker it showed that the positive cTnT( >0.01µg/l) was associated with increased 
mortality (60% sensitivity and with a specificity of 97.5% and P value 0.008) and 
also with subsequent MI (p value0.0001) in ACS patients. 
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In our study when we combined both the markers (hsCRP and cTnT) there 
was a strong association with the occurrence of mortality than either alone.  The 
correlations possibly reflect that coronary inflammation is an ongoing process 
during ACS.  These cutoff values of hs-CRP (> 3 mg/l) and cTnT (>0.01 µg/l) 
could be useful in risk stratification.  Thus the inflammatory marker hs-CRP and 
the biomarker cTnT can be used to predict short term prognosis in patients with 
ACS and could be used to triage the patients and treat them intensively.  
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CONCLUSION 
 
1. In patients with Acute Coronary Syndrome (Unstable angina/NSTEMI) 
elevated hs-CRP was associated with increased mortality (Sensitivity=80%, 
Specificity=98% and p = 0.001). 
 
2. The level of hs-CRP had no association with occurrence of subsequent non 
fatal MI in Unstable angina/NSTEMI patients (p = 0.06). 
 
3. The positive cTnT in patients with Acute Coronary Syndrome (Unstable 
angina/NSTEMI) was associated with increased mortality 
(Sensitivity=60%, Specificity = 97.5% and p=0.008) and also with 
increased occurrence of subsequent non fatal MI. 
 
4. Our results suggest that elevated hs-CRP level(>3mg/l) and positive 
cTnT(>0.01 µg/l) obtained 6 hours after admission in patients with Acute 
Coronary Syndrome can be used as markers for identification of patients 
who are likely to  develop subsequent non fatal MI and mortality.              
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ANNEXURE: A - PROFORMA 
 
 
Name:     Age:    Sex: 
 
Address:    Phone No: 
 
Occupation:    Income: 
 
Date of Admission:   Date of Discharge: 
HISTORY 
 
Chest Pain Y N 
Referred Pain  Y N 
Sweating Y N 
Vomiting Y N 
Palpitation Y N 
Syncope Y N 
Breathlessness  NYHA Class Y / Class N 
Cough Y N 
H/O Orthopnoea Y N 
H/O Paroxysmal Nocturnal Dyspnoea Y N 
H/O Swelling Of The Legs Y N 
H/O Previous Ischemic Heart Disease Y N 
H/O Previous Myocardial Infarction Y N 
Dyslipidemia Y N 
Peripheral Arterial Disease Y N 
H/O  CABG Y N 
H/O  PTCA Y N 
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H/O Stroke Y N 
H/O Surgery In Previous Month Y N 
H/O Diabetes Mellitus Y N 
H/O Hypertension Y N 
History & Features Of SLE  Y N 
History & Features Of Rheumatoid Arthritis Y N 
History & Features Of Scleroderma Y N 
History & Features Of Hepatic Dysfunction  Y N 
History & Features Of Renal Dysfunction Y N 
History & Features Of Malignancy Y N 
Other Rheumatological Disease Y N 
 
Personal history 
Smoking                                Type                      Pk.Yrs  
 
Alcohol                                  Type                      Qty/d              Duration  
 
Tobacco                                Life style 
 
Ht(cm):                                    Wt(Kg):                            BMI:    
 
BP:               mmHg              PR :       /min   Regular/Irregular       
 
Peripheral Pulses:                  RR:      /min                    JVP: 
 
 
 P a g e  | 100 
 
General Examination:  
 
P                   Cl                  Cy                Ln                E                J   
 
System Examination: 
CVS: S1        S2        S3         S4          Additional Sounds: 
RS:                                                       Added Sounds: 
Abdomen: 
CNS:
Investigations 
 
RFT 
Bd.Sugar  
Bd.Urea   
Sr.Creatinine  
Na  
K  
 
Hs CRP:                                             
CTnT : 
CK-MB: 
ECG: 
X- RAY chest: 
 
 
 
URINALYSIS 
Sugar  
Alb  
RBS  
Pus Cells  
Epithelial Cells  
Casts  
 
 
 
HEMOGRAM 
 Hb  
Tc  
Dc P    L    M    E 
Plt.C  
ESR  
Total Cholesterol  
LDL  
HDL  
TGL  
ECHO Cardiogram:  
ST Elevation MI during hospitalisation:  
Death during hospitalisation: 
Readmission as MI: 
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1 KUMAR 55 M 160 75 29.3 Y Y Y Y N N Y N N 202 22 0.8 
2 KATHAVARAYAN 60 M 162 60 22.9 Y Y Y Y N N Y N N 302 36 1.2 
3 KANNAN 65 M 157 63 25.6 N Y N Y N N N N N 132 18 0.76 
4 CHANDRAMOULI 41 M 165 86 31.2 N N N N N N N N N 112 21 0.89 
5 RANGAMANI 55 F 156 72 29.62 N N N Y N N N N N 113 23 0.7 
6 MAHALAKSHMI 35 F 160 66 25.8 N N Y N N N N Y N 278 30 1 
7 JOTHIPRAKASH 53 M 165 76 28.9 N Y N N N N N N N 143 29 0.91 
8 RAMAN 76 M 166 61 22.18 Y Y N Y N N N N N 132 29 1.1 
9 ANWAR HUSSAIN 52 M 169 77 27.01 Y N N Y N N N N N 121 30 0.9 
10 DHANALAKSHMI 40 F 159 59 23.41 N N N N N N N N N 127 31 1 
11 MANOHARAN 52 M 171 69 23.63 N Y Y N N N N N N 321 33 1.5 
12 KILIYAMMAL 58 F 154 66 27.84 N N N Y N N N N N 154 28 0.78 
13 JAYAKUMAR 76 M 164 76 28.35 Y Y Y Y N N N N N 278 31 0.9 
14 SAROJA 55 F 158 58 23.29 N Y N N N N N N N 142 30 1.02 
15 ADIMOOLAM 60 M 169 74 26 N Y N N N N N N N 162 22 0.79 
16 VIJAYA 52 F 159 81 32.14 N Y Y Y N N N N N 223 32 1.1 
17 GNANAMANI 70 F 160 57 22.26 N N N Y N N N N N 109 21 0.93 
18 RAMANI 55 F 162 56 21.37 N Y N Y N N N N N 152 24 0.91 
19 CHINNAPPAN 52 M 163 67 25.28 N Y Y N N N N N N 245 32 0.9 
20 NEELA 77 F 168 72 25.53 N N Y Y N N N N N 256 34 1.3 
21 GOWRI 65 F 171 73 25 N N N Y N N N N N 141 31 0.67 
22 VENGAIYA 49 M 172 68 23.05 Y Y N N N N N N N 117 24 0.91 
23 MUNIYAMMAL 60 F 161 57 22 N N Y Y N N N N N 343 35 1.1 
24 JOICE 66 F 164 68 25.37 N N N N N N N N N 101 26 1 
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1 KUMAR 55 M Y 246 170 34 145 _ 9.8 N N N N 
2 KATHAVARAYAN 60 M Y 198 122 41 156 _ 0.23 P N N N 
3 KANNAN 65 M Y 178 131 45 106 _ 0.75 N N N N 
4 CHANDRAMOULI 41 M Y 112 132 32 166 _ 1.82 N N N N 
5 RANGAMANI 55 F Y 232 177 37 177 _ 1.23 N N N N 
6 MAHALAKSHMI 35 F Y 192 110 43 235 23 11.2 P N N N 
7 JOTHIPRAKASH 53 M Y 187 121 29 198 _ 0.32 N N N N 
8 RAMAN 76 M Y 176 123 34 154 _ 0.11 N N N N 
9 ANWAR HUSSAIN 52 M Y 201 110 42 156 _ 9.6 P N Y N 
10 DHANALAKSHMI 40 F Y 345 207 31 145 _ 17.1 N N N N 
11 MANOHARAN 52 M N 189 246 27 244 _ 0.54 N N N N 
12 KILIYAMMAL 58 F Y 171 129 38 160 _ 0.66 N N N N 
13 JAYAKUMAR 76 M Y 224 173 23 154 _ 1.03 N N N N 
14 SAROJA 55 F Y 201 129 37 167 _ 0.71 N N N N 
15 ADIMOOLAM 60 M Y 191 162 40 155 _ 6.16 P Y N N 
16 VIJAYA 52 F N 234 139 41 144 _ 8.2 N N N N 
17 GNANAMANI 70 F Y 97 98 38 164 _ 0.54 N N N N 
18 RAMANI 55 F Y 108 124 36 154 _ 0.13 N N N N 
19 CHINNAPPAN 52 M Y 179 114 39 167 _ 0.21 N N N N 
20 NEELA 77 F Y 336 202 24 167 _ 0.51 N N N N 
21 GOWRI 65 F Y 103 124 33 143 _ 0.26 N N N N 
22 VENGAIYA 49 M Y 198 181 28 154 _ 1.72 N N N N 
23 MUNIYAMMAL 60 F Y 277 158 33 167 _ 11.72 N N N N 
24 JOICE 66 F Y 197 175 30 153 _ 10.99 N N N N 
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25 PADMAVATHY 70 F 165 70 25.73 N Y Y Y N N N Y N 258 31 0.8 
26 DEVAKI 55 F 159 59 23.41 N Y N Y N N N N N 116 31 1 
27 RAMAMOORTHY 64 M 158 67 26.9 Y N N Y N N N N N 107 22 0.88 
28 SELVARAJ 49 M 162 61 23.28 N Y N N N N N N N 86 21 0.78 
29 POONKAVANAM 43 F 160 62 24.21 N Y N Y N N N N N 98 27 0.91 
30 GOPAL 51 M 160 72 28.12 Y Y N Y N N N N N 188 21 1 
31 SAKUNTHALA 35 F 157 59 23.98 N N Y N N N N N N 223 27 0.83 
32 KOTHANDAM 73 M 174 83 27.48 N Y Y Y N N N N N 114 29 1 
33 SUDAMANI 43 M 171 75 25.68 Y Y Y N N N N N N 277 38 1.3 
34 RAMAN 76 M 170 71 24.43 N Y N Y N N N N N 132 32 1 
35 SELVARAJ 39 M 165 67 24.63 Y N Y N N N N N N 128 25 0.76 
36 ARAVINDKUMAR 49 M 161 60 23.16 Y N Y N N N N N N 198 30 1.1 
37 THANGAMANI 67 F 156 66 29.21 N Y Y Y N N N Y N 223 34 1.3 
38 SANKAR 45 M 159 71 28.17 N N Y N N N N N N 107 23 1 
39 CHANADRA 65 F 160 55 21.48 N Y Y Y N N N N N 244 34 1.1 
40 STELLA 45 F 159 61 24.2 N Y N N N N N N N 118 29 0.92 
41 PETER 52 M 158 54 21.68 Y Y Y Y N N N N N 102 25 0.91 
42 MAHALINGAM 48 M 157 62 25.2 Y Y N Y N N N N N 131 21 1.01 
43 PANDIYAN 61 M 161 67 25.86 Y Y Y Y N N Y N N 211 29 0.9 
44 SAHUL HAMEED 39 M 174 68 22.51 N N N N N N N N N 105 27 1.02 
45 ARUL JYOTHI 45 M 161 69 26.64 Y Y Y N N N N N N 123 31 1.1 
46 RANI 70 F 160 62 24.21 N Y Y Y N N N N N 376 42 1.7 
47 SAKTHIVEL 50 M 158 59 23.69 N Y N Y N N N N N 111 29 0.96 
48 KUMARI 45 F 159 66 26.19 N N N N N N N N N 131 28 1.06 
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25 PADMAVATHY 70 F Y 278 156 30 164 _ 0.73 N N N N 
26 DEVAKI 55 F N 167 130 38 164 _ 1.8 N N N N 
27 RAMAMOORTHY 64 M Y 145 109 27 165 _ 8.87 N N N N 
28 SELVARAJ 49 M Y 208 143 35 207 _ 0.13 N N N N 
29 POONKAVANAM 43 F Y 249 143 37 209 _ 0.51 N N N N 
30 GOPAL 51 M Y 188 134 39 228 25.1 13.1 P Y N N 
31 SAKUNTHALA 35 F Y 197 167 40 239 _ 1.8 N N N N 
32 KOTHANDAM 73 M Y 200 127 39 156 _ 0.62 N N N N 
33 SUDAMANI 43 M Y 191 117 34 123 _ 0.14 N N N N 
34 RAMAN 76 M Y 176 123 34 145 _ 0.3 N N N N 
35 SELVARAJ 39 M N 78 105 32 163 _ 14.57 P N N N 
36 ARAVINDKUMAR 49 M Y 187 211 31 276 _ 0.49 N N N N 
37 THANGAMANI 67 F Y 378 256 21 156 _ 16.15 N N N N 
38 SANKAR 45 M Y 75 121 31 151 _ 0.61 N N N N 
39 CHANADRA 65 F Y 102 124 35 126 _ 8.11 N N N N 
40 STELLA 45 F Y 351 206 27 189 _ 0.42 N N N N 
41 PETER 52 M N 177 126 34 134 _ 0.75 N N N N 
42 MAHALINGAM 48 M Y 197 111 30 152 _ 0.11 N N N N 
43 PANDIYAN 61 M N 166 109 32 106 _ 14.28 P N N N 
44 SAHUL HAMEED 39 M Y 145 119 31 149 _ 0.13 N N N N 
45 ARUL JYOTHI 45 M Y 168 132 39 157 _ 7.2 P N Y N 
46 RANI 70 F Y 154 101 30 164 _ 17.11 N N N N 
47 SAKTHIVEL 50 M Y 176 121 21 163 _ 0.22 N N N N 
48 KUMARI 45 F Y 178 176 33 189 _ 0.61 N N N N 
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49 KUMARESAN 35 M 164 69 25.74 Y N N N N N N N N 122 32 1.01 
50 PANDIYAN 61 M 166 70 25.5 N Y Y Y N N N N N 261 29 1.4 
51 ANNAMALAI 40 M 172 66 22.37 N N N N N N N N N 166 25 0.9 
52 SOKKU 62 M 164 71 26.49 N N Y N N N N N N 132 27 0.99 
53 SAROJA 65 F 165 75 27.57 N Y N Y N N N N N 118 31 1.04 
54 VIJAYAN 65 M 164 73 27.23 Y Y N Y N N N N N 104 24 1 
55 DHANALAKSHMI 45 F 157 58 23.6 N N Y N N N N N N 354 34 1.1 
56 KUPPU 55 F 158 55 22.08 N N N N N N N N N 97 24 0.76 
57 MANI 72 M 160 68 26.56 N N Y Y N N N N N 106 22 0.75 
58 SAJAHAN 60 M 163 65 24.5 N Y N N N N N N N 129 27 1.12 
59 MAHARANI 70 F 160 59 23.04 N Y Y N N N N N N 271 30 1 
60 RAJENDRAN 58 M 163 73 27.54 N N N N N N N N N 114 23 1.19 
61 CHOKKALINGAM 72 M 164 69 25.74 N Y N Y N N N N N 111 28 0.91 
62 NILAVAN 64 M 169 80 28.1 N N Y N N N N N N 308 31 0.9 
63 SAKUNTHALA 69 F 167 70 25.17 N Y Y Y N N N N N 134 31 0.96 
64 SIVAKALAI 60 F 161 71 27.41 Y Y Y N N N N N N 256 28.1 1.1 
65 SOWDABEE 54 F 170 65 22.5 N N N N N N N N N 137 30 1.08 
66 MARIMUTHU 65 M 164 64 23.88 Y N N Y N N N N N 101 27 1 
67 MAJITH 45 M 165 66 24.26 Y N Y N N N N N N 139 29 1.21 
68 PANDURANGAN 76 M 171 67 22.94 N Y Y Y N N N N N 249 27 1 
69 VADIVAMMAL 68 F 170 67 23.18 N Y N N N N N N N 132 29 1.3 
70 CHINNADURAI 50 M 163 68 25.66 N N N Y N N N N N 125 21 0.8 
71 JAMALYA 64 F 165 69 25.36 N Y N Y N N N N N 113 27 0.9 
72 KRISHNAN 65 M 164 68 25.37 N N Y N N N N N N 135 20 0.7 
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49 KUMARESAN 35 M Y 324 189 26 231 _ 0.92 N N N N 
50 PANDIYAN 61 M Y 201 152 29 170 _ 7.67 N N N N 
51 ANNAMALAI 40 M N 199 145 32 302 28 7.2 N N N N 
52 SOKKU 62 M Y 199 126 39 163 _ 0.69 P N N N 
53 SAROJA 65 F N 165 145 31 143 _ 9.2 P Y N N 
54 VIJAYAN 65 M Y 184 166 37 367 _ 0.1 N N N N 
55 DHANALAKSHMI 45 F Y 225 178 29 185 _ 0.24 N N N N 
56 KUPPU 55 F Y 109 142 30 165 _ 0.76 N N N N 
57 MANI 72 M Y 134 144 31 154 _ 10.93 N N N N 
58 SAJAHAN 60 M N 187 122 34 149 _ 0.93 P N N N 
59 MAHARANI 70 F Y 203 123 39 153 _ 0.71 N N N N 
60 RAJENDRAN 58 M Y 89 145 21 134 _ 0.51 N N N N 
61 CHOKKALINGAM 72 M Y 178 129 32 158 _ 0.49 N N N N 
62 NILAVAN 64 M Y 167 190 32 154 _ 3.01 N N Y N 
63 SAKUNTHALA 69 F Y 106 112 36 132 _ 0.56 N N N N 
64 SIVAKALAI 60 F Y 199 158 31 164 21 1.7 P Y N N 
65 SOWDABEE 54 F Y 163 178 34 172 _ 4.52 N N N N 
66 MARIMUTHU 65 M Y 179 111 40 160 _ 0.41 N N N N 
67 MAJITH 45 M Y 81 128 28 162 _ 15.09 P N N N 
68 PANDURANGAN 76 M Y 172 101 33 143 32.1 0.39 P N N         Y 
69 VADIVAMMAL 68 F Y 152 100 37 114 _ 0.71 N N N N 
70 CHINNADURAI 50 M Y 166 108 21 167 _ 1.53 N N N N 
71 JAMALYA 64 F Y 178 99 34 123 _ 0.65 N N N N 
72 KRISHNAN 65 M Y 182 105 31 160 _ 2.92 N N N N 
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73 KONDAIYA 55 M 169 73 25.61 Y N Y Y N N N N N 231 33 1.1 
74 VEERARAGAVAN 68 M 158 70 28.1 N Y N Y N N N N N 139 30 1 
75 LAKSHMIPATHY 63 M 159 75 29.76 Y Y N N N N N N N 122 32 1.12 
76 GUNAMANI 70 F 171 71 24.31 N Y Y Y N N N N N 342 36 1.2 
77 ABDUL JALIL 55 M 159 68 26.98 N N N N N N N N N 132 34 0.74 
78 RAJAMMAL 70 F 158 59 23.69 N Y Y Y N N N N N 235 30 1 
79 SELVARAJ 52 M 157 59 23.98 N N Y N N N N N N 136 23 1 
80 SAMPATH 45 M 163 65 24.52 Y N Y N N N N N N 246 31 1 
81 MAHESH 37 M 160 62 24.21 Y N N N N N N N N 114 21 0.68 
82 GOVINDAMMAL 70 F 159 66 26.2 N Y N Y N N N N N 112 23 0.91 
83 KOWSALYA 75 F 164 63 23.5 N Y N Y N N N N N 131 25 1.01 
84 PERUMAL 62 M 165 64 23.52 N N Y N N N N N N 118 21 1.09 
85 BEER MOHAMAD 75 M 165 68 25 N Y N Y N N N N N 105 24 0.82 
86 MALLIGA 65 F 160 60 23.4 N Y N Y N N N N N 141 29 0.75 
87 SHANKAR 56 M 161 60 23.2 N N N N N N N N N 132 31 1.02 
88 PARVATHY 70 F 173 75 25.08 N Y Y Y N N N Y N 78 27 1.1 
89 GUNASEKARAN 53 M 157 69 19.91 N Y N N N N N N N 106 32 1 
90 MUTHU 38 M 159 68 27 N N N N N N N N N 176 32 1.12 
91 MOHAN 43 M 160 67 26.2 N N N Y N N N N N 143 25 1 
92 DEIVASIGAMANI 36 M 163 69 26 N N N N N N N N N 122 22 0.91 
93 BALAN 61 M 167 70 25.2 Y Y N Y N N N N N 95 22 1.11 
94 RAJENDRAN 60 M 164 69 25.3 N Y N N N N N N N 165 25 0.9 
95 WILLIAM MOSES 78 M 174 72 23.84 N Y N Y N N N N Y 115 22 1 
96 ABUBAKKER 52 M 157 66 26.8 N Y N N N N N N N 131 19 0.97 
 P a g e  | 108 
 
S
.
N
o
 
P
t
 
N
a
m
e
 
A
g
e
 
(
Y
r
s
)
 
S
e
x
 
E
C
G
 
c
h
a
n
g
e
s
 
T
o
t
a
l
 
C
h
o
l
e
s
t
e
r
o
l
 
m
g
/
d
l
 
L
D
L
 
m
g
/
d
l
 
H
D
L
 
m
g
/
d
l
 
T
G
L
 
(
m
g
/
d
l
)
 
C
K
M
B
 
(
n
g
/
m
L
)
 
H
s
C
R
P
 
(
m
g
/
L
)
 
C
T
n
T
 
 
(
µ
g
/
L
)
 
 
S
T
 
e
l
e
v
a
t
i
o
n
 
M
I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d
u
r
i
n
g
 
h
o
s
p
i
t
a
l
 
i
s
a
t
i
o
n
 
D
e
a
t
h
 
d
u
r
i
n
g
 
H
o
s
p
i
t
a
l
 
i
s
a
t
i
o
n
 
R
e
 
a
d
m
i
s
s
i
o
n
 
a
s
 
M
I
 
73 KONDAIYA 55 M Y 198 112 40 161 _ 1.2 N N N N 
74 VEERARAGAVAN 68 M Y 199 112 34 132 _ 1.81 N N N N 
75 LAKSHMIPATHY 63 M Y 156 78 23 167 _ 9.08 N N N N 
76 GUNAMANI 70 F N 309 204 27 212 _ 0.19 N N N N 
77 ABDUL JALIL 55 M Y 200 101 41 165 _ 1.41 N N N N 
78 RAJAMMAL 70 F Y 89 78 34 158 _ 0.7 N N N N 
79 SELVARAJ 52 M Y 276 183 36 176 _ 3.76 N N N N 
80 SAMPATH 45 M Y 210 154 37 289 _ 0.8 N N N N 
81 MAHESH 37 M Y 312 199 31 224 _ 11.43 N N N N 
82 GOVINDAMMAL 70 F Y 87 110 29 98 _ 15.06 N N N N 
83 KOWSALYA 75 F Y 144 89 34 122 _ 0.57 N N N N 
84 PERUMAL 62 M Y 178 112 34 101 _ 1.73 N N N N 
85 BEER MOHAMAD 75 M Y 167 134 31 152 _ 0.52 N N N N 
86 MALLIGA 65 F Y 199 129 39 166 _ 0.42 N N N N 
87 SHANKAR 56 M Y 175 163 32 343 _ 8.7 N N N N 
88 PARVATHY 70 F Y 144 76 30 90 _ 6.58 P N Y N 
89 GUNASEKARAN 53 M Y 243 168 34 143 _ 0.24 N N N N 
90 MUTHU 38 M Y 179 188 32 167 _ 0.32 N N N N 
91 MOHAN 43 M Y 278 134 35 165 _ 0.68 N N N N 
92 DEIVASIGAMANI 36 M N 302 176 38 134 _ 1.02 N N N N 
93 BALAN 61 M Y 77 87 31 166 _ 6.23 N N N N 
94 RAJENDRAN 60 M Y 164 132 41 163 41 0.9 P Y N N 
95 WILLIAM MOSES 78 M Y 103 110 33 99 _ 0.48 N N Y N 
96 ABUBAKKER 52 M Y 225 174 37 134 _ 0.59 N N N N 
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Annexure C – Abbreviation 
 
ABBREVIATION EXPANSION 
ACS Acute corornary syndrome 
AMI acute myocardial infarction 
Ang II angiotensin II 
CAD coronary artery disease 
CKMB cratine kinase myocardial band 
cTn cardiac troponin 
EC endothelial cell 
ECG electrocardiography 
eNOS endothelial nitric oxide synthase 
ET-1 endothelin 1 
GP glycoprotein 
HsCRP highly sensitive C- Reactive protein 
IL interleukin 
ICAM-1 inter cellular adhesion molecule 
iNOS inducible nitric oxide synthase 
LDL low density lipoprotein 
MCP-1 monocyte chemoattractant protein - 1 
MI myocardial infarction 
NF tumor necrosis factor 
NO nitric oxide 
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NSTEMI non ST elevation myocardial infarction 
02
-
 superoxide anion 
ONOO
-
 peroxide 
PAI- 1 plasminogen activator inhibitor 
PGIS prostacyclin synthase 
SMCs smooth muscle cells 
STEMI ST elevation myocardial infarction 
TIMI thrombolysis in myocardial infarction 
TNF tumor necrosis factor 
UA unstable angina 
VCAM-1 vascular cell adhesion molecule 
VSMC vascular smooth muscle cell 
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Annexure D - Ethical committee certificate 
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